Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study
Borja Quiroga,Alberto Ortiz,Sara Núñez,Maria Kislikova,Silvia González Sanchidrián,José Jesús Broseta,Zoila Stany Albines,Beatriz Escamilla Cabrera,Yaiza Rivero Viera,David Rodriguez Santarelli,Laura Salanova Villanueva,Francisca Lopez Rodriguez,Barbara Cancho Castellano,María Ibáñez Cerezon,Carmen Patricia Gutierrez Rivas,Nuria Aresté,Belén Campos Gutiérrez,Ana Ródenas Gálvez,Maria Constanza Glucksmann Pizá,Sagrario Balda Manzanos,Amparo Soldevila,Lucía Rodríguez Gayo,Esperanza Moral Berrio,Mayra Ortega Diaz,Sandra Beltrán Catalán,Adriana Puente García,Miguel Ángel Rojas,R. Haridian Sosa Barrios,Henar Santana Zapatero,Gema Rangel Hidalgo,Ana Maria Martinez Canet,Javier Díez,
DOI: https://doi.org/10.1159/000538030
2024-04-03
Cardiorenal Medicine
Abstract:Introduction. Chronic heart failure (HF) has high rates of mortality and hospitalization in patients with advanced chronic kidney disease (aCKD). However, randomized clinical trials have systematically excluded aCKD population. We have investigated current HF therapy in patients receiving clinical care in specialized aCKD units. Methods. The Heart And Kidney Audit (HAKA) was a cross-sectional and retrospective real-world study including outpatients with aCKD and HF from 29 Spanish centers. The objective was to evaluate how the treatment of HF in patients with aCKD complied with the recommendations of the European Society of Cardiology Guidelines for the diagnosis and treatment of HF, especially regarding the foundational drugs: renin-angiotensin system inhibitors (RASi), angiotensin receptor blocker/neprilysin inhibitors (ARNI), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Results. Among 5012 aCKD patients, 532 (13%) had a diagnosis of HF. Of them, 20% had reduced ejection fraction (HFrEF), 13% mildly reduced EF (HFmrEF), and 67% preserved EF (HFpEF). Only 9.3% of patients with HFrEF were receiving quadruple therapy with RASi/ARNI, BB, MRA and SGLT2i, but the majority were not on the maximum recommended doses. None of the patients with HFrEF and CKD G5 received quadruple therapy. Among HFmrEF patients, approximately half and two-thirds were receiving RASi and/or BB, respectively, while less than 15% received ARNI, MRA or SGLT2i. Less than 10% of patients with HFpEF were receiving SGLT2i. Conclusions. Under real-world conditions, HF in aCKD patients is sub-optimally treated. Increased awareness of current guidelines and pragmatic trials specifically enrolling these patients represent unmet medical needs.
cardiac & cardiovascular systems,urology & nephrology